Kerri Fitzgerald

Cancer Nursing Today nonprod

Decitabine with or without ruxolitinib is beneficial for patients with advanced myeloproliferative neoplasms (MPN) when initiated early in the disease course prior to the development of MPN blast-phase (BP) disease, according to a study published in Acta Haematologica.&nbsp;The retrospective study included 42 patients treated with decitabine alone or in combination with ruxolitinib; 16 patients had with MPN-BP, 14 had MPN accelerated-phase (MPN-AP), and 12 had myelofibrosis with high-risk features (MF-HR).Median overall survival (OS) for patients with MPN-BP was 2.6 months, and for those who received two or more cycles of decitabine therapy, it was 6.7 months (95% confidence interval, 3.8-29.8). Patients with MPN-BP with a poor performance status and who required hospitalization at the time of the initiation of decitabine had a poor prognosis.After a median follow-up of 12.4 months for patients with MPN-AP and 38.7 months for patients with MF-HR, median OS was not reached for either cohort; at 60 months, one and two patients, respectively, were alive.The probability of spleen length reduction and transfusion independence within 12 months of initiating decitabine was 28.6% and 23.5%, respectively. The combination of decitabine and ruxolitinib improved OS (21.0 months) compared with single-agent decitabine (12.9 months).

Decitabine Plus Ruxolitinib Demonstrates Clinical Benefit in Patients With MPN

Decitabine with or without ruxolitinib is beneficial for patients with advanced MPN when initiated early in the disease course prior to the development of MPN blast-phase disease.

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Lung Cancer

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe